Shenaz Bagha News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Shenaz bagha. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Shenaz Bagha Today - Breaking & Trending Today
Treatment with belimumab resulted in fewer flares in patients with either early or established systemic lupus erythematosus, especially among those with no baseline organ damage, according to data presented at the EULAR 2024 Congress. “The benefits of early treatment of SLE for the prevention of repeated flares of disease activity, as well as the need to limit glucocorticoid exposure, are ....
An FDA advisory panel on Monday voted in favor of donanemab as a treatment for early symptomatic Alzheimer’s disease.In a press conference on June 10, the Peripheral and Central Nervous System Drugs Advisory Committee ruled 11-0 that donanemab (Eli Lilly & Co.), a once-per-month, 30-minute infusion treatment, was effective in treating individuals with mild cognitive impairment and mild ....
The ability to view laboratory results, track symptoms and sharing them with a provider were rated as the most useful potential app functions by patients with rheumatic and musculoskeletal diseases, according to data.“As patient education continues to transition from paper to online resources, it is important to understand how education and other patient needs could be satisfied in a ....
Serious infections were uncommon among patients with psoriatic arthritis exposed to targeted therapies for the first time in “a large and exhaustive” French cohort, according to data published in RMD Open.Compared with new users of adalimumab (Humira, Abbvie), risk for serious infection was significantly lower among new users of etanercept (Enbrel, Immunex) and ustekinumab (Stelara, ....
The monoclonal antibody Uplizna met key endpoints in a phase 3 trial for the treatment of IgG4-related disease, marking the first time a placebo-controlled study has shown benefit in the condition, according to a press release from Amgen.Topline results from the double-blind, randomized trial, called MITIGATE, demonstrated an 87% reduced risk for IgG4-related disease (IgG4-RD) flare in patients ....